• Cancel
    Date：2024-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=775

    Recently, Blue Sail Medical (002382.SZ) announced that its cardiovascular and cerebrovascular business unit, Blue Sail Biosensors, has raised a total of RMB 1 billion in funding. The Series A2 round introduced an additional RMB 100 million, following a RM

  • Cancel
    Date：2024-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=771

    On February 21, 2024, Yantai Dongcheng Biochemicals (002675) announced that its wholly-owned subsidiary, Yitai Pharmaceutical, intends to purchase the 99mTc-GSA injection and GSA cold kit (hereinafter referred to as the "target product") held by Rongcheng

  • Cancel
    Date：2023-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=708

    Columbia China and Nanyan Group announce Nanyan Group's acquisition of Columbia China's clinic business. CEC Capital acted as exclusive financial advisor to Columbia China in this transaction.

  • Cancel
    Date：2023-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=710

    Qingdao PHAGEPHARM Biotechnology Co., Ltd. ("PHAGEPHARM" or “Company”), a leading domestic provider of phage-resistant comprehensive solutions, completed a Series B financing round of nearly RMB 100 million. This financing was led by Cenova Capital, with participation from Morningside Ventures and two existing shareholders. CEC Capital served as exclusive financial advisor for this transaction.

  • Cancel
    Date：2022-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=721

    BioMérieux recently entered a strategic investment partnership with Accunome Biotechnology Co., Limited ("Accunome"), which includes an equity investment and an exclusive distribution agreement. This partnership signifies a deep collaboration between BioM

  • Cancel
    Date：2022-06

    Exclusive Financial Advisor to the founders of Taikang Bybo Dental

  • Cancel
    Date：2022-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=732

    Fosun Pharmaceutical recently announced that its subsidiary, YanengBIO, along with its existing shareholders, has entered into a relevant agreement with Yaneng Bioscience under CBridge Capital. Upon completion of the transaction, YanengBIO will transition

  • Cancel
    Date：2022-01

    Financial Advisor to PAG

  • Cancel
    Date：2021-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=802

    CBridge Capital, a healthcare-focused investment firm, recently announced its investment in Beijing Anhejialier Technology Co., Ltd. ("Anhejialier"), a leading company in the field of ultrasonic knives. This investment represents CBridge Capital's strong